Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY2140023 added to atypical antipsychotic treatment in schizophrenia with prominent negative symptoms
2009-016245-26Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing LY2140023 + background atypical antipsychotic with Placebo + background atypical antipsychotic (2 arms). Started Nov 2009; status: completed.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2009-016245-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016245-26.